International Journal of Clinical Research

The problem of myopia has become a global public health challenge that affects the quality of life of people in all corners of the world. According to recent statistics, it is not difficult to find that the global incidence of myopia and high myopia is increasing. This increasing trend not only brings great pressure and burden to the social economy, but also high myopia may increase the risk of irreversible blindness eye disease, which will seriously affect the quality of life [1]. In view of this situation, it is particularly urgent and critical to find effective ways to slow down and even stop the occurrence and progression of myopia. Currently, there are various methods to correct myopia, including the use of [2] such as muscarinic antagonists, orthokeratology lenses, multifocal glasses, and traditional frame glasses. Among these methods, low concentrations of atropine, as one of the muscarinic antagonists, have shown remarkable effects in controlling myopia progression in children and adolescents. This paper aims to make a systematic summary of the clinical research of low-concentration atropine in delaying the progression of myopia, and to prospect the possibility of its future application, hoping to provide new ideas and methods for the prevention and treatment of myopia.

Low concentration; Atropine; Control of myopia; Clinical progress